 |
471 Diseases |  |
207 Trials |
|
207 Trials |  |
10577 News |  |
| «12...1112131415161718192021...132133» |
- everolimus / Generic mfg.
IMPACT OF IMMUNOSUPPRESSIVE REGIMEN TO ANTIBODY RESPONSE AFTER CHADOX1 NCOV-19 VACCINATION IN THAI KIDNEY TRANSPLANT RECIPIENTS (Focussed Oral Room 7) - May 4, 2023 - Abstract #ERAEDTA2023ERA_EDTA_2109;
KTRs who received TAC/EVR/CS regimen had highest immune response after vaccination, which is relatively comparable to healthy control in Thailand. Immunosuppressive regimen should be considered for vaccine dose and schedule in the future.
- Epogen (epoetin alfa) / Amgen, Jardiance (empagliflozin) / Eli Lilly, Boehringer Ingelheim
SAFETY AND EFFICACY OF SODIUM-GLUCOSE COTRANSPORTER 2 INHIBITORS IN KIDNEY TRANSPLANT PATIENTS WITH TYPE 2 OR POST-TRANSPLANT DIABETES (Focussed Oral Room 7) - May 4, 2023 - Abstract #ERAEDTA2023ERA_EDTA_2084;
SGLT2i may be an option for the management of DM in KT patients, improving glycemic control and cardiovascular risk factors. An adequate selection, hygienic recommendations and surveillance of urinary infections are important.No
- prednisone / Generic mfg., everolimus / Generic mfg.
EXERCISE AND PREDIABETES AFTER RENAL TRANSPLANTATION: THE EXPRED I STUDY (Focussed Oral Room 7) - May 4, 2023 - Abstract #ERAEDTA2023ERA_EDTA_2030;
Therapeutic exercise is safe and effective to improve glucose metabolism in renal transplant patients with prediabetes. Adherence is a crucial aspect to consider in the planification of exercise treatment.
- everolimus / Generic mfg.
USE OF GLUCAGON-LIKE PEPTIDE 1 RECEPTOR AGONISTS IN KIDNEY TRANSPLANT PATIENTS: A MULTI-CENTER STUDY. (Focussed Oral Room 7) - May 4, 2023 - Abstract #ERAEDTA2023ERA_EDTA_2027;
Our results support that it can be an option for the management of DM in these patients. Its use is safe and it does not seem to alter tacrolimus trough levels, to induce AR episodes or de novo DSAs development.No
- Savaysa (edoxaban) / Daiichi Sankyo, Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
ANTICOAGULANT RELATED NEPHROPATHY (Focussed Oral Room 2) - May 4, 2023 - Abstract #ERAEDTA2023ERA_EDTA_1855;
Attention should be given to drug interactions that can induce an unrecognized OAC. The cases described underline the need for careful monitoring of U, RFx and FXa activity to promptly treat this complication, avoiding permanent damage.Figure.1.
- RETURN TO DIALYSIS AFTER KIDNEY TRANSPLANTATION, A REALITY OF TODAY. DESCRIBING OUR EXPERIENCE. (Focussed Oral Room 4) - May 4, 2023 - Abstract #ERAEDTA2023ERA_EDTA_1637;
Withdrawal of immunosuppression was performed on a median of 10 months, faster in mTOR and antimetabolites, and more progressive in CNI and steroids. Stop IS before the first year is more common in haemodialysis group and it is associated with a higher rate of graft intolerance.
- | Lenvima (lenvatinib) / Eisai, Merck (MSD), Cabometyx (cabozantinib tablet) / Exelixis
Trial completion date, Trial primary completion date, Checkpoint inhibition, Metastases: Lenvatinib With Everolimus Versus Cabozantinib for Second-Line or Third-Line Treatment of Metastatic Renal Cell Cancer (clinicaltrials.gov) - May 3, 2023
P2, N=90, Recruiting, Sponsor: M.D. Anderson Cancer Center
Stop IS before the first year is more common in haemodialysis group and it is associated with a higher rate of graft intolerance. Trial completion date: Apr 2023 --> Apr 2024 | Trial primary completion date: Apr 2023 --> Apr 2024
- | Enrollment closed, Tumor mutational burden: The Rome Trial From Histology to Target: the Road to Personalize Target Therapy and Immunotherapy (clinicaltrials.gov) - May 3, 2023
P2, N=384, Active, not recruiting, Sponsor: Fondazione per la Medicina Personalizzata
Trial completion date: Apr 2023 --> Apr 2024 | Trial primary completion date: Apr 2023 --> Apr 2024 Recruiting --> Active, not recruiting
- || everolimus / Generic mfg.
P1 data, PK/PD data, Journal: Pharmacokinetic Drug-Drug Interaction With Coadministration of Cannabidiol and Everolimus in a Phase 1 Healthy Volunteer Trial. (Pubmed Central) - May 3, 2023
Log-transformed everolimus maximum concentration, AUC from time of dosing to the last measurable concentration, and AUC extrapolated to infinity values increased by ?2.5-fold, and everolimus half-life remained largely unchanged in the presence of steady-state CBD relative to everolimus dosed alone. Everolimus blood concentration monitoring should be strongly advised with appropriate dose reduction when coadministered with CBD.
- || Inlyta (axitinib) / Pfizer, Sutent (sunitinib) / Pfizer
Trial completion date, Trial primary completion date, HEOR, Real-world evidence, Real-world, Metastases: ADONIS: Study Of The Impact Of Inlyta In 2nd Line On The Treatment Outcomes Of mRCC Patients Treated With Sutent In 1st Line In The Real Life Setting (clinicaltrials.gov) - May 1, 2023
P=N/A, N=573, Completed, Sponsor: Pfizer
Everolimus blood concentration monitoring should be strongly advised with appropriate dose reduction when coadministered with CBD. Trial completion date: Apr 2021 --> Sep 2022 | Trial primary completion date: Apr 2021 --> Sep 2022
- | everolimus / Generic mfg.
New P2 trial: EVERLAST: Everolimus Aging Study (clinicaltrials.gov) - May 1, 2023
P2, N=86, Recruiting, Sponsor: University of Wisconsin, Madison
- everolimus / Generic mfg.
The Incubation of Sucrose Craving Does Not Require MTOR Activity (Sapphire AB) - Apr 29, 2023 - Abstract #SOBP2023SOBP_362;
Herein, we examine whether the FDA-approved mTOR inhibitor Everolimus can similarly block incubated sucrose-seeking...Conclusions Unlike incubated cocaine-craving, incubated sucrose-craving is not correlated with elevated mTOR activity within prefrontal cortex subregions, nor does it require mTOR activation. These data indicate that the incubation of drug- and sucrose-seeking involve distinct molecular adaptations within prefrontal cortex.
- || Avastin (bevacizumab) / Roche
Clinical, Retrospective data, Journal: Meta-analysis of commonly mutated genes in leptomeningeal carcinomatosis. (Pubmed Central) - Apr 29, 2023
In conclusion, a total of 96 mutated genes in LMC were investigated via meta-analysis. Our findings suggested vital roles of TP53, PTEN, PIK3CA, KMT2D, and IL7R, which can provide insight into the molecular basis of LMC development and paving the door to the development of new targeted medicine and will encourage molecular biologists to seek biological evidence.
- | Avastin (bevacizumab) / Roche
Preclinical, Journal: Clinically relevant glioblastoma patient-derived xenograft models to guide drug development and identify molecular signatures. (Pubmed Central) - Apr 28, 2023
Best treatment responses were observed for standard of care temozolomide, irinotecan and bevacizumab...In models sensitive for mTOR inhibitor everolimus, hypoxia-related gene sets reactive oxygen species pathway and angiogenesis were enriched...Available matching orthotopic PDX models can be used to assess the impact of the tumor microenvironment and blood-brain barrier on efficacy. Our GBM PDX panel therefore represents a valuable platform for screening regarding molecular markers and pharmacologically active drugs, as well as optimizing delivery of active drugs to the tumor.
- | navitoclax (ABT 263) / AbbVie
Preclinical, Journal: Zebrafish Patient-Derived Xenograft Model as a Preclinical Platform for Uveal Melanoma Drug Discovery. (Pubmed Central) - Apr 28, 2023
This approach allowed for the experimental replications required for reliable drug screening (at least 2 individual biological experiments, with n > 20). Drug treatments with navitoclax and everolimus validated the zebrafish patient-derived model as a versatile preclinical tool for screening anti-UM drugs and as a preclinical platform to predict personalized drug responses.
- || everolimus / Generic mfg., sirolimus / Generic mfg.
Review, Journal: An Evidence-Based Update on the Potential Association between Rheumatoid Arthritis and Lymphangioleiomyomatosis. (Pubmed Central) - Apr 28, 2023
In addition, extensive research is essential for understanding the potential connection between these two disorders and discovering any similar mechanisms involved that may underlie their occurrence. This may contribute to the development of new therapeutic options that target shared pathways implicated in the pathogenesis of RA and LAM.
- | everolimus / Generic mfg.
New P2/3 trial: Addition of Everolimus to Standard of Care in Carcinoma Gallbladder (clinicaltrials.gov) - Apr 27, 2023
P2/3, N=56, Recruiting, Sponsor: Banaras Hindu University
- everolimus / Generic mfg., gemcitabine / Generic mfg.
Synergistic anti-tumor activity of the mTOR inhibitor everolimus and gemcitabine for the treatment of peripheral T cell lymphoma. () - Apr 26, 2023 - Abstract #ASCO2023ASCO_6208;
This may contribute to the development of new therapeutic options that target shared pathways implicated in the pathogenesis of RA and LAM. Collectively, our study sheds light on synergistic antitumor effect of combinatorial therapy, providing a potential therapeutic strategy for patients with R/R PTCL.
- Votrient (pazopanib) / Novartis
Retrospective analysis of the multikinase inhibitor (MKI) pazopanib in differentiated thyroid carcinoma (DTC) in the beyond-first-line setting. () - Apr 26, 2023 - Abstract #ASCO2023ASCO_5719;
Pazopanib was associated with durable PFS and good tolerability when offered after PD or intolerance on lenvatinib in this retrospective analysis, warranting a randomized prospective study. >
- Lenvima (lenvatinib) / Eisai, Merck (MSD)
Salvage lenvatinib/everolimus (LE) combination therapy after immune checkpoint inhibitor (ICI) and VEGFR tyrosine kinase inhibitor (TKI) for metastatic renal cell carcinoma (mRCC). () - Apr 26, 2023 - Abstract #ASCO2023ASCO_5320;
Pts with favorable risk, prior nephrectomy or early salvage may have a better treatment response. These observations need to be confirmed in prospective studies.
- The emerging use of immunotherapy as a treatment option in metastatic renal cell carcinoma: Real-world evidence from a single UK tertiary cancer centre. () - Apr 26, 2023 - Abstract #ASCO2023ASCO_5310;
The results of our real-world evaluation of prescribing practices in mRCC favoured the use of combination immunotherapy in the first-line setting for the treatment of IMDC intermediate- and poor-risk clear cell mRCC with similar outcomes to the published data in the CheckMate 214 trial. The overall trend towards improved PFS in the first 6 months in our local dataset highlights the importance of patient selection when using immunotherapy.
- Margenza (margetuximab) / MacroGenics, ZAI Lab, Lumakras (sotorasib) / Amgen
No checkmate in metastatic setting: Navigating real world patients applying personalized therapy based on extensive tumor profiling. () - Apr 26, 2023 - Abstract #ASCO2023ASCO_4730;
ETP offers a chance for a majority of late stage patients often characterized by visceral crisis to prolong PFS with acceptable ECOG status. ETP is a milestone as cancer itself is a complex disease with the need for complex solutions.
- Ibrance (palbociclib) / Pfizer
Outcome of second-line treatment after CDK4/6 inhibitors in hormonal-positive HER-2 negative metastatic breast cancer: Single institution experience. () - Apr 26, 2023 - Abstract #ASCO2023ASCO_4279;
Outcome of 2nd line systemic therapy following first line palbociclib with hormonal therapy was poor in the study cohort. No significant difference in PFS according to type of systemic therapy, duration of first line therapy, or other clinicopathological factors.
- everolimus / Generic mfg.
Open-label phase II study of everolimus plus endocrine therapy in postmenopausal women with ER+, HER2- metastatic breast cancer (Chloe trial). () - Apr 26, 2023 - Abstract #ASCO2023ASCO_4278;
Although the addition of mTOR inhibitors may have suppressed the deterioration of patient status, several cases required discontinuation due to AE associated with the drug. Further study with a larger sample size may be required to determine a significant difference between the two groups.
- BPI-16350 / Betta Pharma
BPI-16350, a novel promising CDK4/6 inhibitor for HR+/HER2- metastatic breast cancer (MBC): Results from a phase I study. () - Apr 26, 2023 - Abstract #ASCO2023ASCO_4277;
P1, P3
A phase III study (NCT05433480) comparing BPI-16350 plus FUL versus placebo plus FUL in pts with MBC is ongoing. Clinical trial information: NCT03791112.
- defactinib (VS-6063) / Verastem, avutometinib (VS-6766) / Verastem
RAMP 202: A phase 2 study of avutometinib (VS-6766) (On Demand | Hall A; Poster Bd # 88) - Apr 26, 2023 - Abstract #ASCO2023ASCO_3509;
P2
In this heavily pretreated population of patients with KRAS G12V mt NSCLC, limited clinical activity was observed with combination therapy. While no new safety signals were identified, criteria to proceed to part B were not met, and further evaluation of avutometinib
- giredestrant (GDC-9545) / Roche
evERA Breast Cancer (BC): Phase III study of giredestrant + everolimus vs exemestane + everolimus in patients (pts) with estrogen receptor-positive, HER2-negative locally advanced or metastatic BC (ER+, HER2 (On Demand | Hall A; Poster Bd # 336a) - Apr 26, 2023 - Abstract #ASCO2023ASCO_3311;
P3
While no new safety signals were identified, criteria to proceed to part B were not met, and further evaluation of avutometinib Fulvestrant
- Piqray (alpelisib) / Novartis, Kisqali (ribociclib) / Novartis, Nerlynx (neratinib) / Puma, Knight Therap, Pierre Fabre
Imbalance in treatment discontinuation without progression between experimental and control arms among randomized trials in advanced breast cancer. (On Demand | Hall A; Poster Bd # 331) - Apr 26, 2023 - Abstract #ASCO2023ASCO_3302;
all the statistically significant imbalanced TD in the RCT were in experimental arms. Quantitative association between imbalanced TD and the ratio of HR for PFS/OS suggests imbalanced TD may impact ability to translate improvements in PFS to OS.
- everolimus / Generic mfg., erlotinib / Generic mfg., dasatinib / Generic mfg.
Biological Medicines for Diffuse Intrinsic Pontine Glioma (DIPG) Eradication (BIOMEDE): Final results of an international randomized phase II platform trial comparing 3 targeted therapies in combination with radiotherapy from ITCC, SIOPE-Brain and ANZCHOG. (Live Stream | S100a) - Apr 26, 2023 - Abstract #ASCO2023ASCO_3197;
P2
This trial demonstrated the feasibility and safety of a large randomized trial for DIPG based on biomarker information from a stereotactic biopsy at diagnosis in an international multicenter setting and generated new tumor biological insights to further develop innovative therapies. Clinical trial information: NCT02233049.
- Piqray (alpelisib) / Novartis
Disparities in PI3K/mTOR inhibitor use, toxicities, and outcomes among patients with metastatic breast cancer. (On Demand | Hall A; Poster Bd # 89) - Apr 26, 2023 - Abstract #ASCO2023ASCO_2696;
Efforts to improve access to these life-prolonging agents are warranted. Of concern, we also found racial disparities in toxicity outcomes, with Black patients having twice the risk of hyperglycemia.
- Libtayo (cemiplimab) / Regeneron
Cemiplimab for kidney organ transplant recipients with advanced cutaneous squamous cell carcinoma: CONTRAC-1. (On Demand | S406; Poster Bd # 282) - Apr 26, 2023 - Abstract #ASCO2023ASCO_2600;
P1
Durable anti-tumor efficacy was observed. mTOR inhibition with prednisone should be the preferred IS regimen when treating KTRs with anti-PD-1 therapy.
- Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD), Sutent (sunitinib) / Pfizer
Final prespecified overall survival (OS) analysis of CLEAR: 4-year follow-up of lenvatinib plus pembrolizumab (L+P) vs sunitinib (S) in patients (pts) with advanced renal cell carcinoma (aRCC). (Live Stream | Hall D1) - Apr 26, 2023 - Abstract #ASCO2023ASCO_2137;
P3
mTOR inhibition with prednisone should be the preferred IS regimen when treating KTRs with anti-PD-1 therapy. Treatment-na
- everolimus / Generic mfg.
Adjuvant everolimus in patients (Pts) with localized non-clear cell renal cell carcinoma (RCC): Subgroup analysis from the Everest trial (SWOG S0931). (On Demand | Hall A; Poster Bd # 38) - Apr 26, 2023 - Abstract #ASCO2023ASCO_2047;
P3
The estimated everolimus HRs for DFS and OS in the chRCC subset are consistent with the overall trial result, but those same modest HRs were not seen in papRCC, in contrast to prior reports of mTOR inhibitor activity in this subtype. Although inferences are limited by sample size and wide CIs, this is the largest experience in chRCC or papRCC among any adjuvant trials presented to date.
- FUTURE-SUPER: A randomized, subtyping-based umbrella phase II trial for first-line treatment of metastatic triple-negative breast cancer. (On Demand | S100bc; Poster Bd # 209) - Apr 26, 2023 - Abstract #ASCO2023ASCO_1870;
P1/2, P2
Our findings highlight the profound clinical benefits with treatment optimization according to molecular/immunological subtypes in TNBC, outlining a direction for further exploration. Clinical trial information: NCT04395989.
- Proposition of a drug score to predict the clinical usefulness of therapeutic dose monitoring of oral molecularly targeted therapies. (On Demand | Hall A; Poster Bd # 289) - Apr 26, 2023 - Abstract #ASCO2023ASCO_1792;
We defined a score to identify good candidates for TDM in onco-hematology. Usefulness of TDM in oncology should be confirmed prospectively prioritizing these molecules.
- Bavencio (avelumab) / EMD Serono, Reolysin (pelareorep) / Oncolytics, Andrus Reo
BRACELET-1 (PrE0113): Inducing an inflammatory phenotype in metastatic HR+/HER2- breast cancer with the oncolytic reovirus pelareorep in combination with paclitaxel and avelumab. (On Demand | S406) - Apr 26, 2023 - Abstract #ASCO2023ASCO_1450;
P2
One third of patients discontinued either pelareorep or avelumab due to toxicity, highlighting the need for attentive supportive care. Survival data is maturing.
- ||| everolimus / Generic mfg.
ILD/Pneumonitis is more specific to TDxD (or everolimus, IO) rather than being a class effect for all ADCs. Thankfully, ILD is not a common SE with sacituzumab. Though we have to worry about diarrhea, neutropenia, and hair loss (hair loss also seen with TDxD) (Twitter) - Apr 26, 2023
- | Journal: Three generations of mTOR kinase inhibitors in the activation of the apoptosis process in melanoma cells. (Pubmed Central) - Apr 25, 2023
There is a need for research on the search for new therapeutic strategies aimed at particular groups of patients. Effect of three generations of mTOR kinase inhibitors on caspase-3 activity, apoptosis and proliferation in melanoma cell lines.
- |||| Enhertu (fam-trastuzumab deruxtecan-nxki) / Daiichi Sankyo, AstraZeneca, everolimus / Generic mfg., capecitabine / Generic mfg.
Clinical: 65yo patient with de novo, HR+ HER2-low (IHC 1+) mBC, PS ECOG 1. Progressed on: - AI/palbo (PFS 5 years) - fulv/everolimus (PFS 8 months) - capecitabine (PFS 3 months) - starts T-DXd on 8/2022, with PR. 🫁 4/2023: develops G2 ILD (cough). ❓what next, after resolution of ILD? (Twitter) - Apr 25, 2023
- | acarbose / Generic mfg.
Trial completion date, Trial initiation date, Trial primary completion date, Combination therapy, Immunomodulating, Metastases: Acarbose in Combination With Standard Therapy in Metastatic Renal Cell Carcinoma (RCC) (clinicaltrials.gov) - Apr 24, 2023
P2, N=24, Not yet recruiting, Sponsor: University of Alabama at Birmingham
Effect of three generations of mTOR kinase inhibitors on caspase-3 activity, apoptosis and proliferation in melanoma cell lines. Trial completion date: Dec 2024 --> Dec 2026 | Initiation date: Feb 2023 --> Nov 2023 | Trial primary completion date: Jul 2024 --> Jul 2025
- | prednisone / Generic mfg., everolimus / Generic mfg., sirolimus / Generic mfg.
Enrollment change: Comparison of the Efficacy and Safety of Sirolimus Versus Everolimus Versus Mycophenolate in Kidney Transplantation (clinicaltrials.gov) - Apr 24, 2023
P4, N=1209, Completed, Sponsor: Hospital do Rim e Hipertens
Trial completion date: Dec 2024 --> Dec 2026 | Initiation date: Feb 2023 --> Nov 2023 | Trial primary completion date: Jul 2024 --> Jul 2025 N=319 --> 1209
- | Biomarker, New P2 trial, Circulating tumor DNA, Metastases: Levels of Circulating Tumor DNA as a Predictive Marker for Early Switch in Treatment for Patients With Metastatic (Stage IV) Breast Cancer (clinicaltrials.gov) - Apr 24, 2023
P2, N=500, Not yet recruiting, Sponsor: University of Miami
- |||| Zarnestra (tipifarnib) / Kura Oncology, everolimus / Generic mfg.
Clinical: “Molecularly matched treatment was administered to 19 patients (4 NEC, 15 NET): immunotherapy (n = 3), tipifarnib (n = 1), NOTCHi (n = 1), EGFRi (n = 2), HER2i (n = 1) and everolimus (n = 11)” 11 of 19 got mTORi. Cant read too much into outcomes here as mTORi works regardless. (Twitter) - Apr 23, 2023
- ||| Actinium-225 DOTATATE (RYZ101) / BMS
Enrollment open, Metastases: ACTION-1: Study of RYZ101 Compared With SOC in Pts w Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy (clinicaltrials.gov) - Apr 21, 2023
P1b, N=218, Recruiting, Sponsor: RayzeBio, Inc.
N=319 --> 1209 Active, not recruiting --> Recruiting
- everolimus / Generic mfg.
CVT-SFA-trial: First report of 6 months results using a new Everolimus coated balloon technology (ROOM 4 ) - Apr 20, 2023 - Abstract #LINC2023LINC_204;
- | Stivarga (regorafenib) / Bayer
Retrospective data, Journal: Safety and efficacy of multiple tyrosine kinase inhibitors in pediatric/adolescent and young adult patients with relapsed or refractory osteosarcomas: A single-institution retrospective analysis. (Pubmed Central) - Apr 19, 2023
The safety profile of MTKI therapies in pediatric and AYA patients was comparable to that in adult patients. MTKI therapies, particularly regorafenib, against pediatric relapsed osteosarcoma can suppress tumor growth and prolong PFS with tolerable adverse events.
- |||| Ostarine (enobosarm) / Veru Inc
Trial completion date, Trial primary completion date, Monotherapy, Metastases: ARTEST: Efficacy Evaluation of Enobosarm Monotherapy in Treatment of AR+/ER+/HER2- Metastatic Breast Cancer (clinicaltrials.gov) - Apr 18, 2023
P3, N=210, Active, not recruiting, Sponsor: Veru Inc.
MTKI therapies, particularly regorafenib, against pediatric relapsed osteosarcoma can suppress tumor growth and prolong PFS with tolerable adverse events. Trial completion date: Apr 2023 --> Jul 2023 | Trial primary completion date: Mar 2023 --> Jun 2023
- |||| Enrollment open, Trial primary completion date: STAPOVER: Signal TrAnsduction Pathway Activity Analysis in OVarian cancER (clinicaltrials.gov) - Apr 18, 2023
P2/3, N=148, Recruiting, Sponsor: Gynaecologisch Oncologisch Centrum Zuid
Trial completion date: Apr 2023 --> Jul 2023 | Trial primary completion date: Mar 2023 --> Jun 2023 Not yet recruiting --> Recruiting | Trial primary completion date: Oct 2025 --> Oct 2026
- ||||| everolimus / Generic mfg., RMC-6236 / Revolution Medicines, avutometinib (VS-6766) / Verastem
Remarkable data by @udai_banerji and team! Always surprising us with something new! That's one dramatic 🫁 #NSCLC #KRAS G12D response! Added @ASCO (22) avutometinib/ everolimus data for context. Perhaps, combo with PAN-KRASi RMC-6236 (AACR23 data) would be of interest! https://t.co/1TEAbkKWC1 (Twitter) - Apr 18, 2023
- |||| everolimus / Generic mfg., avutometinib (VS-6766) / Verastem
Intermittent dosing and smart combinations. Love it when a plan comes together abstract 3461 #AACR23 avutometinib+everolimus for the treatment of non-G12C KRAS mutated NSCLC @ICR_DDU_IIT @ICR_London @royalmarsdenNHS @ECMC_UK @cancerBRC (Twitter) - Apr 17, 2023